Top Active Trader Stock Alerts (ADBE, BIIB, DB, MSFT, SEED, RIMM, VICL, VVUS)

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Active traders and day traders have several key stocks to watch.  We are tracking moves in Adobe Systems, Inc. (NASDAQ: ADBE), Biogen Idec Inc. (NASDAQ: BIIB), Deutsche Bank AG (NYSE: DB), Microsoft Corporation (NASDAQ: MSFT), Origin Agritech Limited (NASDAQ: SEED), Research in Motion Limited (NASDAQ: RIMM), Vical Incorporated (NASDAQ: VICL), and VIVUS, Inc. (NASDAQ: VVUS).

Adobe Systems, Inc. (NASDAQ: ADBE) is down sharply after revenue forecasts were shy of expectations, like the Apple woes did not signal that.  Share sare down 20% at $26.27 on active trading.  The 52-week range is $26.01 – $38.20.

Biogen Idec Inc. (NASDAQ: BIIB) is getting hit after Novartis got an MS drug approval from the FDA that could be a rival to Biogen’s MS franchise.  Shares are down almost 5% at $55.45.

Deutsche Bank AG (NYSE: DB) is getting a bit of a recovery after seeing shares hit yesterday.  So far the ADR is up 2% at $55.25.

Microsoft Corporation (NASDAQ: MSFT) sees that no good deed goes unpunished after announcing a debt raise and dividend boost.  Shares are down 1.15% at $24.86 on over 200,000 shares.

Origin Agritech Limited (NASDAQ: SEED) is up after it reached a worldwide agreement with the Institute of Plant Protection, Chinese Academy of Agricultural Sciences (CAAS), which jointly owns the rights to the internally developed Bt-gene.  Shares are trading up 9.22% at $8.29 on over 40,000 shares.

Research in Motion Limited (NASDAQ: RIMM) is seeing shares trade up almost 1% at $47.60 after word of a rival for the tablet PC and after TheStreet.com said it could possibly double.

Vical Incorporated (NASDAQ: VICL) is getting squashed on news that it and Sanofi’s Ischemia drug failed late stage trials.  Shares are down 35% at $2.50 on over 40,000 shares.

VIVUS, Inc. (NASDAQ: VVUS) shares are up close to 6% at $7.14 on over 70,000 shares after Canaccord raised the rating and on continued positive news about its obesity drug candidate.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. a673b.bigscoots-temp.com.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618